Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vixotrigine - Biogen

Drug Profile

Vixotrigine - Biogen

Alternative Names: 1014802; BIIB 074; CNV 1014802; CNV 1014802 A; GSK 1014802 A; GSK1014802; Raxatrigine

Latest Information Update: 28 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen; GlaxoSmithKline
  • Class Analgesics; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain; Trigeminal neuralgia

Highest Development Phases

  • Phase III Trigeminal neuralgia
  • Phase II Erythromelalgia; Neuropathic pain
  • Discontinued Bipolar disorders; Sciatica

Most Recent Events

  • 20 Sep 2021 Efficacy and adverse event data from the phase II CONVEY study in Small fiber neuropathy released by Biogen
  • 05 May 2021 Biomarkers information updated
  • 05 May 2021 Biogen terminates a phase-II clinical trial in Neuropathic pain in Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Spain, Switzerland and in the UK, due to sponsors decision (PO) (NCT03339336) (EudraCT2017-000991-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top